OFF LABEL USE OF ALTEPLASE FOR ACUTE ISCHEMIC STROKE (AIS) IN PATIENTS OVER 80 YEARS OF AGE: INDIVIDUAL-PATIENT-DATA META-ANALYSIS OF EIGHT TRIALS
World Stroke Academy. Hacke W. May 16, 2017; 183377 Disclosure(s): Boehringer Ingelheim, Daiichi-Sankyo, Neuravi, Medtronic, Boehringer Ingelheim (for ECASS 4 EXTEND), German Research Foundation, German Ministry of Science, European Union
Prof. Werner Hacke
Prof. Werner Hacke
Login now to access Regular content available to all registered users.

Access to Premium content is currently a membership benefit.

You may also access WSO content "anytime, anywhere" with the FREE World Stroke Academy App for iOS and Android.
Discussion Forum (0)
Rate & Comment (0)
Code of conduct/disclaimer available in General Terms & Conditions

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies